| Meliodays Medical–Capacura: investment, 202503 pre-seed financing round totalling >€800k incl lead investor Capacura GmbH |
2025-03-20 |
| Meliodays Medical–FS Life Science Investment: investment, 202503 pre-seed financing round totalling >€800k incl co-investor FS Life Science Investment |
2025-03-20 |
| Anbio Biotechnology–SEVERAL: investment, 202502 IPO $8m net $7.44m at Nasdaq Global Market with 1.6m Class A ordinary shares at $5/share |
2025-02-18 |
| Bürkert Fluidic Control Systems–Green Elephant Biotech: cell culture technology, 202502 strategic partnership incl strategic investment by Bürkert |
2025-02-13 |
| Green Elephant Biotech–Bürkert Fluidic Control Systems: investment, 202502 strategic investment by Bürkert as part of strategic partnership |
2025-02-13 |
| Akribion–Bruker: investment, 202502 seed financing round totalling €8m incl co-investor Bruker Invest |
2025-02-04 |
| Akribion–Carma Fund: investment, 202502 seed financing round totalling €8m incl co-lead investor Carma Fund |
2025-02-04 |
| Akribion–Hessen (govt): investment, 202502 seed financing round totalling €8m incl co-investor Hessen Kapital I |
2025-02-04 |
| Akribion–High-Tech Gründerfonds: investment, 202502 seed financing round totalling €8m incl co-investor HTGF |
2025-02-04 |
| Akribion–Optimum Strategic Communications: public relations, 202502 service existent by Optimum |
2025-02-04 |
| Akribion–Putsch (Recaro): investment, 202502 seed financing round totalling €8m incl co-investor MP Beteiligungs-GmbH |
2025-02-04 |
| Akribion–SEVERAL: investment, 202502 seed financing round €8m led by Carma Fund + RV Invest |
2025-02-04 |
| Akribion–Vetter: investment, 202502 seed financing round totalling €8m incl co-lead investor RV Invest |
2025-02-04 |
| IBA Lifesciences–Cube Biotech: investment, 202501 acquisition of IBA Lifesciences by Cube Biotech backed by majority owner Archimed |
2025-01-13 |
| HUB Organoids–Merck (DE): investment, 202412– acquisition €na of HUB Organoids Holding BV by Merck SIGNED |
2024-12-17 |
| Mainz Biomed–SEVERAL: investment, 202412 follow-on offering $8m with 1.37m units (1 share + 1 Class A + 1 Class B warrant) at $5.85/unit |
2024-12-16 |
| Eppendorf–DataHow: laboratory software, 202412– collab strategic integration of DataHowLab s/w with BioNSight cloud |
2024-12-02 |
| Biotheus–BioNTech: investment, 202411– acquisition 100% for $800m upfront mostly in cash + few ADSs plus $150m milestones |
2024-11-13 |
| Mainz Biomed–Thermo Fisher: colorectal cancer screening test, 202411– collab developm + commercialisation assays for mRNA-based CRC screening tests |
2024-11-12 |
| Mediaire–High-Tech Gründerfonds: investment, 202411 financing round totalling €12m incl existing + co-investor HTGF |
2024-11-12 |
| Zymofix–High-Tech Gründerfonds: investment, 202411 financing round totalling €2m incl lead investor HTGF |
2024-11-12 |
| Complihealth–Bertelsmann: investment, <=202411 investment by new investor Bertelsmann Investments in Guardoc Health |
2024-11-07 |
| Doccla–Bertelsmann: investment, <=202411 investment by existing investor Bertelsmann Investments |
2024-11-07 |
| Pi Health–Bertelsmann: investment, <=202411 investment by new investor Bertelsmann Investments |
2024-11-07 |
| Aignostics–Boehringer: investment, 202410 financing round Series B totalling $34m incl existing + co-investor BIVF |
2024-10-29 |
| Aignostics–High-Tech Gründerfonds: investment, 202410 financing round Series B totalling $34m incl existing + co-investor HTGF |
2024-10-29 |
| Danaher–CrestOptics: spinning disk microscopy, 202410– collab integration of Cicero spinning disk unit into Thunder Imager of Leica Microsystems |
2024-10-07 |
| Austrian Academy of Sciences–Boehringer: grant, 202409–203608 funding €150m establishment + operation of AITHYRA Institute over 12y by BIS |
2024-09-18 |
| Symphera–High-Tech Gründerfonds: investment, 202409 seed financing round totalling €2.4m incl lead investor HTGF |
2024-09-16 |
| Abolis Biotechnologies–Evonik: investment, 202409 financing round totalling €35m incl investor Evonik Venture Capital |
2024-09-12 |
| Mainz Biomed–Liquid Biosciences: AI-based cancer diagnostics, 202409– collab expansion using EMERGE platform to advance PancAlert screening test |
2024-09-04 |
| Saiba Animal Health–Boehringer: investment, 202409 acquisition €na of Saiba Animal Health AG by Boehringer Ingelheim |
2024-09-03 |
| PL BioScience–Avant Bio: investment, 202408 financing round Series A totalling €7.8m incl new investor Avant Bio LLC |
2024-08-08 |
| PL BioScience–b.value: investment, 202408 financing round Series A totalling €7.8m incl new investor b.value AG |
2024-08-08 |
| PL BioScience–Better Ventures: investment, 202408 financing round Series A totalling €7.8m incl new investor Better Ventures |
2024-08-08 |
| PL BioScience–Brightlands Venture Partners: investment, 202408 financing round Series A totalling €7.8m incl existing investor BVP Fund IV |
2024-08-08 |
| PL BioScience–LePure Biotech: investment, 202408 financing round Series A totalling €7.8m incl new investor LePure Biotech |
2024-08-08 |
| PL BioScience–SEVERAL: investment, 202408 financing round Series A €7.8m with new + existing investors |
2024-08-08 |
| PL BioScience–TechVision Fonds: investment, 202408 financing round Series A totalling €7.8m incl existing investor TechVision Fonds |
2024-08-08 |
| IDRx–Merck (DE): investment, 202408 financing round Series B totalling $120m incl existing + co-investor Merck KGaA |
2024-08-07 |
| Carbios–MC Services: public relations, 202408 service existent MC Services Is media contact for DACH + UK |
2024-08-06 |
| BASF–Biomatter Designs: enzyme design, 202408 supply existent customer BASF |
2024-08-05 |
| Synthetica Pioneering–Boehringer: investment, 202407 financing round Series A incl co-lead investor Boehringer Ingelheim Venture Fund |
2024-07-30 |
| Nerio Therapeutics–Boehringer: investment, 202407 acquisition up to $1.3b of Nerio Therapeutics by Boehringer |
2024-07-29 |
| Deepc–Bertelsmann: investment, 202407 financing round Series A extension totalling €13m incl existing + co-lead investor Bertelsmann Investments |
2024-07-25 |
| BioNTech–Triastek: 3D drug printing, 202407– collab developm + license $10m upfront + $1.2b milestones plus royalties 3D printed oral RNA drugs |
2024-07-23 |
| BioSpring–Pantherna Therapeutics: mRNA therapeutics, 202407– collab strategic alliance €na developm + licensing of mRNA molecules for genome editing |
2024-07-15 |
| HepaRegenix–Boehringer: investment, 202407 financing round Series C totalling €15m incl existing + co-investor BIVF |
2024-07-10 |
| HepaRegenix–High-Tech Gründerfonds: investment, 202407 financing round Series C totalling €15m incl existing + co-investor HTGF |
2024-07-10 |
| SciRhom–High-Tech Gründerfonds: investment, 202407 financing round Series A totalling €63m incl existing + co-investor HTGF |
2024-07-09 |
| Nyxoah–MC Services: public relations, 202407 service existent MC Services Is Media Contact for International + Germany |
2024-07-03 |
| Pentixapharm–MC Services: public relations, 202407 service existent by MC Services |
2024-07-03 |
| Carelane–High-Tech Gründerfonds: investment, 202406 pre-seed financing round totalling €800k incl lead investor HTGF |
2024-06-20 |
| Tacalyx–Boehringer: investment, 202406 seed financing round expansion totalling €7m incl existing + co-investor BIVF |
2024-06-11 |
| Tacalyx–Creathor Ventures: investment, 202406 seed financing round expansion totalling €7m incl existing + co-investor Creathor Ventures |
2024-06-11 |
| Tacalyx–Germany (govt): investment, 202406 seed financing round expansion totalling €7m incl existing + co-investor Coparion |
2024-06-11 |
| Tacalyx–High-Tech Gründerfonds: investment, 202406 seed financing round expansion totalling €7m incl existing + co-investor HTGF |
2024-06-11 |
| Mirus Bio–Merck (DE): investment, 202405–202408 acquisition $600m by Merck from controlling stakeholder Gamma Biosciences (KKR) |
2024-05-22 |
| Insempra–Henkel: investment, 202405 financing round Series A totalling $20m incl new investor Henkel dx Ventures |
2024-05-07 |
| Cultimate Foods–b.value: investment, 202404 seed financing round totalling €2.3m incl co-investor b.value AG |
2024-04-23 |
| Cultimate Foods–High-Tech Gründerfonds: investment, 202404 seed financing round totalling €2.3m incl lead investor HTGF |
2024-04-23 |
| Prothea Technologies–North Rhine-Westphalia (govt): investment, 202404 financing round Series A totalling €12m incl co-investor NRW.BANK |
2024-04-09 |
| Merck (DE)–Caris Life Sciences: AI-based drug discovery, 202404– collab strategic up to $1.4b discovery of cancer targets for ADC RnD |
2024-04-04 |
| Merz–Acorda Therapeutics: neurological drugs, 202404–202407 acquisition $185m of Inbrija + Ampyra + related assets from bankrupt Acorda |
2024-04-02 |
| Perspix Biotech–BioCopy: investment, 20403 acquisition of Perspix Biotech GmbH by BioCopy AG + renamed to BioCopy Analytix GmbH |
2024-03-20 |
| Asgard Therapeutics–Boehringer: investment, 202403 financing round Series A totalling €30m incl existing + co-investor BIVF |
2024-03-14 |
| Tubulis–Germany (govt): investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Coparion |
2024-03-14 |
| Tubulis–High-Tech Gründerfonds: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor HTGF |
2024-03-14 |
| Boehringer–Sosei: GPR52 agonists, 202403– collab drug discovery + excl ww license option €25m upfront + €730m milestones plus tiered royalties |
2024-03-11 |
| Merck (DE)–C4 Therapeutics: protein degradation drugs, 202403– license + collab $16m upfront + $740m milestones + royalties discovery of 2 degraders |
2024-03-04 |
| BRAIN Biotech–Putsch (Recaro): credit, 202402–202609 convertible bond €5m with MP Beteiligungs-GmbH at 6.52% p.a. |
2024-02-29 |
| Cyclize–High-Tech Gründerfonds: investment, 202402 seed financing round totalling €4.75m incl co-investor HTGF |
2024-02-21 |
| Evonik–Univ Mainz: lipid vectors, 202402– license for rPEG lipids for nucleic acid delivery from Univ Mainz |
2024-02-20 |
| Boehringer–CBmed: cancer drugs, 202402– collab long-term strategic alliance €na using translational medicine to develop personalised cancer treatments |
2024-02-08 |
| Rhineland-Palatinate (govt)–Axa: business park management, 202401– collab of Kadans Science Partner Deutschland + Technologiezentrum Mainz for biotech |
2024-01-29 |
| Disco Pharmaceuticals–AbbVie: investment, 202401 seed financing round totalling €20m incl co-investor AbbVie Ventures |
2024-01-16 |
| Disco Pharmaceuticals–Merck (DE): investment, 202401 seed financing round totalling €20m incl co-investor M Ventures |
2024-01-16 |
| Disco Pharmaceuticals–Panakés Partners: investment, 202401 seed financing round totalling €20m incl co-investor Panakés Partners |
2024-01-16 |
| Disco Pharmaceuticals–SEVERAL: investment, 202401 seed financing round €20m led by Sofinnova Partners |
2024-01-16 |
| Disco Pharmaceuticals–Sofinnova: investment, 202401 seed financing round totalling €20m incl lead investor Sofinnova Partners |
2024-01-16 |
| BioNTech–WuXi PharmaTech: drug discovery services, 202401– supply discovery of MAb candidates $20m upfront + milestones + royalties by WuXi Biologics |
2024-01-11 |
| BioNTech–JPMorgan Chase: investor conference, 202401 supply service BioNTech presents at JP Morgan Healthcare Conference 2024 |
2024-01-09 |
| Merck (DE)–Inspirna: ompenaclid, 202401– license excl ww ex-US $45m upfront + milestones + royalties |
2024-01-04 |
| Paion–Humanwell Healthcare: investment, 202312 acquisition of essential business operation of insolvent Paion AG + Paion Deutschland GmbH |
2023-12-22 |
| Odyssey Therapeutics–BlackMars Capital: investment, 202312 financing round Series C totalling $101m incl co-investor BlackMars Capital |
2023-12-05 |
| Boehringer–IBM: AI-based drug discovery, 202311– collab generativa AI + foundation models for development of therapeutic antibodies |
2023-11-28 |
| WMT AG–FS Life Science Investment: investment, 202311 investment by FS Investment in WMT as part of current bridge financing |
2023-11-28 |
| WMT AG–High-Tech Gründerfonds: investment, 202311 existent HTGF is existing investor in WMT |
2023-11-28 |
| T3 Pharmaceuticals–Boehringer: investment, 202311 acquisition of T3 Pharma for up to CHF450m by Boehringer Ingelheim |
2023-11-22 |
| RED Horticulture–ECBF: investment, 202311 financing round Series A totalling €17m incl new + lead investor ECBF |
2023-11-21 |
| Mainz Biomed–Liquid Biosciences: AI-based cancer diagnostics, 202311– collab using EMERGE platform to advance ColoAlert CRC screening test |
2023-11-09 |
| Merck (DE)–Hengrui: cancer drugs, 202310– strategic alliance €160m upfront + total up to €1.4b license HRS-1167 + option SHR-A1904 ww excl China |
2023-10-30 |
| FarmInsect–High-Tech Gründerfonds: investment, 202310 financing round Series A totalling €8m incl existing + co-investor HTGF |
2023-10-23 |
| BioNTech–MediLink Therapeutics: antibody-drug conjugates, 202310– collab + ww license excl China $70m upfront + $>1b milestones for anti-HER3 ADC |
2023-10-12 |
| Japan Tobacco–Max Planck: drug discovery, 202310– collab up to 7 years with Lead Discovery Center + its academic network |
2023-10-11 |
| Kranus Health–High-Tech Gründerfonds: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-investor HTGF |
2023-10-02 |
| AexeRNA Therapeutics–BioNTech: investment, 202310 acquisition €na of AexeRNA by BioNTech |
2023-10-01 |
| Abivax–MC Services: public relations, 202309 service existent MC Services is European investor relations contact |
2023-09-29 |
| Mainz Biomed–Cantor Fitzgerald: investor conference, 202309 supply service Mainz Biomed presents at CF Global Healthcare Conference 2023 in NY |
2023-09-28 |
| Traceless Materials–b.value: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor b.value |
2023-09-25 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
